Dr Avinash Ignatius - Nephrologist and Transplant Physician

04/02/2026

01/02/2026

31/01/2026

31/01/2026

28/01/2026

Limit salt intake, watch for hidden sources.
NOTE: For most kidney patients- low sodium salts can be dangerous, as they have a high potassium content.

18/01/2026

Vitestra's Aletta Autonomous Robotic Phlebotomy Device - facilitating blood draws - Will it some day simplify the puncture of challenging AV fistulas?

18/01/2026

Studies have revealed that limiting sugar in a baby’s first two years of life significantly reduces the long-term risk of developing chronic diseases like Type 2 Diabetes and high blood pressure.

The first 1,000 days of a child’s life - from conception through the first two years of life - is a crucial period for rapid development of the brain, metabolism and learning.

Early high sugar intake can change how the body metabolizes food, leading to increased fat storage, which contributes to obesity and related disease.

Excessive exposure to sugar in the first two years (even in the womb) can lead to metabolic changes that predispose a child to obesity and other metabolic disorders later in life.

Also, the taste buds and preferences are developed in the first few years of life. Consuming a lot of sugar early on can create a lasting preference for sweet foods, making it more difficult to consume a healthy diet in adulthood.

To help, parents can be mindful once the baby arrives and focus on keeping the child’s sugar intake low, especially during the first two years and opt for sugars found naturally in whole foods like fruits, which also provide fiber and other nutrients rather than added sugars.

PMID: 39480913

18/01/2026

The Health Ministry’s NEET PG cutoff relaxation divides medical bodies. IMA supports filling seats, while FORDA and FAIMA warn it undermines merit and profes...

16/01/2026

Important for kidney patients to protect against vaccine preventable infections…

(Note: The new PCV 20 pneumococcal vaccine is once in a lifetime, unlike the previous- that needed 5 yearly booster)

14/01/2026

A major pharma company's billion-dollar bet on using AI in drug discovery!

My favorite kind of collaboration that I've been talking about for years: a pharma company teaming up with a tech giant, instead of looking at them as a competitor!

NVIDIA and Eli Lilly just announced the launch of a Co-Innovation AI Lab that will bring together a world-leading, multidisciplinary team of scientists, AI researchers and engineers to address the hardest problems in drug discovery.

They will also pioneer robotics and physical AI to accelerate and scale medicine discovery and production.

"𝑇ℎ𝑖𝑠 𝑗𝑜𝑖𝑛𝑡 𝑐𝑜-𝑖𝑛𝑛𝑜𝑣𝑎𝑡𝑖𝑜𝑛 𝑙𝑎𝑏 𝑏𝑒𝑡𝑤𝑒𝑒𝑛 𝐸𝑙𝑖 𝐿𝑖𝑙𝑙𝑦 𝑎𝑛𝑑 𝐶𝑜𝑚𝑝𝑎𝑛𝑦 𝑎𝑛𝑑 𝑁𝑉𝐼𝐷𝐼𝐴 𝑓𝑜𝑙𝑙𝑜𝑤𝑠 𝑜𝑛 𝑡𝑜𝑝 𝑜𝑓 𝑏𝑢𝑖𝑙𝑑𝑖𝑛𝑔 𝑡ℎ𝑒 𝑖𝑛𝑑𝑢𝑠𝑡𝑟𝑦'𝑠 𝑚𝑜𝑠𝑡 𝑝𝑜𝑤𝑒𝑟𝑓𝑢𝑙 𝑠𝑢𝑝𝑒𝑟𝑐𝑜𝑚𝑝𝑢𝑡𝑒𝑟 𝑙𝑎𝑠𝑡 𝑦𝑒𝑎𝑟. 𝑀𝑜𝑠𝑡 𝑖𝑚𝑝𝑜𝑟𝑡𝑎𝑛𝑡𝑙𝑦, 𝑡ℎ𝑒𝑠𝑒 𝑎𝑟𝑒 𝑛𝑜𝑡 𝑗𝑢𝑠𝑡 𝑎 𝑙𝑜𝑡 𝑜𝑓 𝑟𝑒𝑠𝑜𝑢𝑟𝑐𝑒𝑠 𝑡ℎ𝑎𝑡 𝑏𝑜𝑡ℎ 𝑐𝑜𝑚𝑝𝑎𝑛𝑖𝑒𝑠 𝑝𝑢𝑡 𝑖𝑛, 𝑏𝑢𝑡 𝑤𝑒 𝑎𝑟𝑒 𝑏𝑢𝑖𝑙𝑑𝑖𝑛𝑔 𝑎 𝑡𝑟𝑢𝑙𝑦 𝑗𝑜𝑖𝑛𝑡 𝐿𝑖𝑙𝑙𝑦/𝑁𝑉𝐼𝐷𝐼𝐴 𝑡𝑒𝑎𝑚 𝑜𝑓 𝐴𝐼 𝑠𝑐𝑖𝑒𝑛𝑡𝑖𝑠𝑡𝑠, 𝑐ℎ𝑒𝑚𝑖𝑠𝑡𝑠, 𝑏𝑖𝑜𝑙𝑜𝑔𝑖𝑠𝑡𝑠 𝑎𝑛𝑑 𝑒𝑛𝑔𝑖𝑛𝑒𝑒𝑟𝑠, 𝑐𝑜𝑙𝑙𝑜𝑐𝑎𝑡𝑒𝑑 𝑖𝑛 𝑎 𝑗𝑜𝑖𝑛𝑡 𝑓𝑎𝑐𝑖𝑙𝑖𝑡𝑦 𝑎𝑡 𝑡ℎ𝑒 ℎ𝑒𝑎𝑟𝑡 𝑜𝑓 𝑆𝑖𝑙𝑖𝑐𝑜𝑛 𝑉𝑎𝑙𝑙𝑒𝑦."

Expect similar news from other pharma companies; however, Lilly took the biggest step forward by working together with the leading tech giant in the AI race.

Source: https://nvidianews.nvidia.com/news/nvidia-and-lilly-announce-co-innovation-lab-to-reinvent-drug-discovery-in-the-age-of-ai

14/01/2026